Viewing nowCombinationJanumet 50/850 mg Tablet
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 202204366 · Approved 2022.12.05 · Insurance code 653806210
Improves glycemic control in patients with type 2 diabetes
This medication helps patients with type 2 diabetes to control their blood sugar levels more effectively. Sitagliptin and Metformin work together to complement meal and exercise therapy, improving blood sugar levels. Thus, taking this medication can enhance blood sugar management and assist in diabetes treatment.
For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: In patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy, or in patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).
This medication is used to assist in blood sugar control for the treatment of diabetes. However, a serious allergic reaction may occur during treatment, so caution is warranted. If symptoms such as anaphylaxis, angioedema, or severe skin conditions occur, discontinue use immediately and consult a physician. Additionally, acute pancreatitis, a serious inflammation of the pancreas, may occur; therefore, if symptoms such as abdominal pain, nausea, or vomiting arise, inform healthcare personnel immediately. Patients with severe renal dysfunction, acute heart disease, or acute infectious states should not take this medication. It is also advisable for women who are pregnant, may become pregnant, or breastfeeding not to take this medication. This medication may cause hypoglycemia; therefore, great care should be taken during skipped meals or intense exercise. Furthermore, if used in conjunction with other antidiabetic drugs or insulin, the risk of hypoglycemia may increase, so it should be taken according to a doctor's instructions. Possible gastrointestinal disturbances, headaches, and cold-like symptoms may occur during treatment; if any of these symptoms are severe or persistent, consult a physician. This medication can affect liver and kidney function; hence, regular blood tests and kidney function assessments are necessary. Elderly patients or those with compromised renal function should be monitored more closely. Excessive alcohol consumption may increase the risk of side effects from this medication, so alcohol should be avoided. If surgical procedures are planned, it may be necessary to pause this medication temporarily; therefore, inform healthcare personnel of any surgical plans. If new symptoms or unusual reactions occur while taking this medicine, inform a physician immediately for appropriate action.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that protects it from air and kept at room temperature, between 1 and 30 degrees Celsius. Proper storage helps maintain the efficacy of the medication for a longer period.
A dark pink oval film-coated tablet
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.